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Abstract: Background: Evaluating histologic grade for breast cancer diagnosis is standard and
associated with prognostic outcomes. Current challenges include the time required for manual mi-
croscopic evaluation and interobserver variability. This study proposes a computer-aided diagnostic
(CAD) pipeline for grading tumors using artificial intelligence. Methods: There were 138 patients
included in this retrospective study. Breast core biopsy slides were prepared using standard labo-
ratory techniques, digitized, and pre-processed for analysis. Deep convolutional neural networks
(CNNs) were developed to identify the regions of interest containing malignant cells and to segment
tumor nuclei. Imaging-based features associated with spatial parameters were extracted from the
segmented regions of interest (ROIs). Clinical datasets and pathologic biomarkers (estrogen receptor,
progesterone receptor, and human epidermal growth factor 2) were collected from all study subjects.
Pathologic, clinical, and imaging-based features were input into machine learning (ML) models to
classify histologic grade, and model performances were tested against ground-truth labels at the
patient-level. Classification performances were evaluated using receiver-operating characteristic
(ROC) analysis. Results: Multiparametric feature sets, containing both clinical and imaging-based
features, demonstrated high classification performance. Using imaging-derived markers alone, the
classification performance demonstrated an area under the curve (AUC) of 0.745, while modeling
these features with other pathologic biomarkers yielded an AUC of 0.836. Conclusion: These results
demonstrate an association between tumor nuclear spatial features and tumor grade. If further
validated, these systems may be implemented into pathology CADs and can assist pathologists to
expeditiously grade tumors at the time of diagnosis and to help guide clinical decisions.
Keywords: breast cancer; Nottingham grade; tumor; biopsy; imaging biomarkers; computational
oncology
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1. Introduction
Pathologic assessment is essential for breast cancer (BC) diagnosis and provides im-
portant histologic information to guide therapy. Standard specimen reporting guidelines
from the College of American Pathologists (CAP; 2021) recommend biomarker analysis
on diagnostic biopsies, including estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor-2 (HER2), for invasive breast carcinomas [1].
The CAP breast protocol also includes reporting histologic type, lymphovascular space
involvement, and histologic grade as standard practice [1]. All of these parameters are
important markers used to inform clinical decisions in breast oncology. Histologic grade
was first introduced by Bloom and Richardson (1957), then modified by Elston and Ellis
(1991), and is widely known today as the Nottingham grade [2]. The grading system is a
semiquantitative method to assess morphological characteristics of tumor cells, specifically
scoring tubule formation, nuclear pleomorphism, and mitotic activity. The combined score
from these subcomponents results in classification among three grades (i.e., Nottingham
grade 1–3), which signifies the level of differentiation from normal breast epithelial cells [2].
In terms of clinical utility, previous studies have shown an association to survival end-
points [3] and response to therapy [4], and recent guidelines from the American Joint
Committee on Cancer (AJCC) have incorporated histologic grade into staging information,
which is used, in part, to guide treatment strategies [5,6].
Manual annotations involve specimen preparation, sectioning, staining with hema-
toxylin and eosin (H&E), and evaluation under brightfield microscopy. Challenges as-
sociated with manual scoring approaches have been reported, including reproducibility
issues and interobserver variability [2,7,8], with Kappa values reported between 0.43 to
0.85 [2,9,10]. However, one of the greatest challenges is the high demand on pathology
resources, including the time required to evaluate cases. This is impacted by fluctuations in
expertise and the need to manage other pathology tasks, such as administrative and opera-
tional functions [11,12]. To address these challenges, there is great interest in developing a
stratification pipeline to identify and prioritize high-risk cases for expedited review [11,13].
Recent shifts toward high-resolution digital pathology imaging and the rapid growth in
artificial intelligence (AI) in medicine have afforded exciting opportunities to achieve this
by developing computational pathology, specifically computer-aided diagnostic (CAD)
systems in pathology.
CAD systems have been developed in other medical specialties, including breast
radiology, with the primary task of detecting and segmenting tumor masses on mammog-
raphy [14]. In pathology, there are similar applications, i.e., AI-assisted tools to detect
malignant regions on whole slide images (WSIs). Indeed, this has been the focus of sev-
eral studies targeting lung [15], prostate [16,17], nasopharyngeal [18], and gynecological
malignancies [19]. Developing CADs for breast cancer pathology is an area of clinical
importance. In part, this is due to the biological complexity of breast tumors, and there
is a need to initiate treatments early for high-risk disease, which depends on rapid diag-
noses [20]. Automation to enhance efficiency and standardization to improve accuracy are
important principles in this realm as well. Although CADs for breast pathology are under-
going development, several deep learning (DL) architectures for macroscopic region-based
segmentation have been proposed using convolutional neural networks (CNNs) [21–24].
Similarly, DL architectures have been proposed for microscopic analysis of individual
tumor cells and nuclei contained in the regions of interest (ROI), and this has the potential
to yield richer information about tumor activity by using high-throughput computing to
evaluate fine-grain tumor patterns and microscopic characteristics. Quantitating morpho-
logical and spatial attributes may provide insight into cell–cell interactions and characterize
aggressive phenotypes, such as high histologic grade (i.e., Nottingham G3). Within this
framework, CADs directed for microscopic analyses can fulfil three fundamental opera-
tions on diagnostic WSIs: (1) object recognition (e.g., cell and nuclear detection amidst the
parenchymal background), (2) object classification (e.g., labeling tumor cells and nuclei
from other cell types and stromal background), and (3) feature extraction (e.g., quantitative
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digital pathology imaging markers) [21,25]. The opportunities include validating features
as markers for prognosis, treatment endpoints, and tumor phenotyping.
Several networks for microscopic object detection and segmentation have been pro-
posed for breast biopsies [26–29]. Janowczyk et al., reported an efficient pipeline to segment
breast tumor nuclei [28]. Their study included 137 breast cancer cases containing 141 re-
gions for analysis using a so-called resolution adaptive deep hierarchical (RADHicaL)
learning scheme [28]. The algorithm is predicated on a pixel-wise classification approach
and includes a pre-processing step to rescale input images to increase computational
efficiency. The DL backbone comprises an adapted AlexNet for classification [28]. The
adaptive algorithm demonstrated good classification performances; the true-positive rate
(TPR) and positive predictive value (PPV) were 0.8061 and 0.8822, respectively [28]. Other
research has focused on automated immunohistochemistry (IHC) to evaluate biomarkers,
such as HER2 [30]. Vandenberghe et al. compared two computational pipelines to analyze
breast tumors, which used imaging features to carry out classification tasks. The first model
consisted of a machine learning (ML) workflow, and performances were compared to a
deep neural network. The CNN outperformed conventional ML models and showed an
overall accuracy of 0.78 as well as demonstrated high concordance to pathologists’ assess-
ments [30]. Overall, these studies demonstrate the ongoing interest to enhance automation
for breast cancer diagnosis. In this present study, we build on our previous work [31–33] to
develop CADs for pathology and propose a computational pipeline for histologic grading.
2. Methods
2.1. Patients and Dataset
A summary of the methods and analysis pipeline is presented in Figure 1. This
study was a non-consecutive retrospective, single-institution study. All study parameters
were approved by the institutional research ethics board prior to data collection and
analysis. The study cohort consisted of biopsy-confirmed breast cancer patients who
underwent anthracycline and taxane-based neoadjuvant chemotherapy (NAC) between
2013–2018 at Sunnybrook Health Sciences Centre (Toronto, ON, Canada). Patients were
excluded from the study based on the following criteria: incomplete reporting of clinical-
pathological data, metastatic disease presentation, incomplete course of NAC treatment,
and administration of trial agents. Additionally, patients with invasive lobular carcinoma
(ILC) were excluded from the study, as higher mitotic count of ILC correlates with higher
stage and decreased survival; both nuclear pleomorphism and tumor architecture have not
been shown to be prognostically significant [34,35]. Furthermore, their spatial organization
demonstrates distinct patterns previously characterized as linear cellular arrangements,
sheets, or nests [36].
Pathological reporting of Nottingham grade (G1, G2, G3) on pre-treatment core needle
biopsies (CNB) was used as the ground truth labels for this study. As the primary aim of
the study’s pipeline was to identify high-risk breast cancer (G3), the patients that presented
with G1 or G2 were combined into a single class of low-intermediate grades. Tumor grade
was reported by board-certified pathologists as part of the patient’s standard of care.
Other clinicopathologic data collection included patient age (years) and receptor
status (ER, PR, HER2). ER, PR, and HER2 receptor status was assessed by immunohisto-
chemistry (IHC); tumors with a HER2-equivocal score underwent dual-probe fluorescent
and/or silver in-situ hybridization (FISH/SISH) to confirm the HER2 status. ER, PR, and
HER2 status were defined using the American Society of Clinical Oncology (ASCO)/CAP
guidelines [37–39]. All clinical and pathological data were extracted from the institution’s
electronic medical record system. Other markers, such as Ki-67 immunohistochemistry,
were not collected, as this was not part of the institution’s standard of care.
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Figure 1. Nottingham grade classification pipeline. (a) (i) A representative H&E stained CNB section is first tiled, followed
by stain normalization (ii), then used as input to a CNN (modified VGG19), which predicts the tumor bed probabilities
(iii). A heatmap is generated using the tumor bed probabilities (iv). Tiles from the tumor bed are then used as input for the
Mask R-CNN, which segments the malignant nuclei (v). (b) Spatial and clinical features are extracted. Spatial features were
extracted using the centroids of the segmented nuclei. The spatial features included density features (vi), graph features
(vii), and nuclei count. Clinicopathological features, including patient age (years) and receptor status (ER, PR, HER2).
(c) Separate machine learning models were trained for spatial and clinical features. The clinical and spatial models were
then combined to create an ensemble model. The ensemble model was evaluated on the hold-out (test) set.
2.2. Specimen Preparation
CNBs were sectioned from formalin-fixed paraffin-embedded (FFPE) blocks, micro-
tomed into 4 µm sections, and stained using H&E. Specimens were prepared onto glass
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slides for imaging. A commercially available digital pathology image scanner (TissueScope
LE, Huron Digital Pathology Inc., St. Jacobs, ON, Canada) was used to digitize slides
into WSI at high magnification (40×). Quality checks were performed on all WSI prior
to analysis; all samples were verified for blurriness, staining irregularities, and external
artifact contamination.
2.3. WSI Pre-Processing and Tumor Bed Identification
The first step in the digital analysis of the WSI was to separate the tissue (foreground)
from the background. Tissue separation was accomplished by implementing Otsu thresh-
olding and morphological operations (binary closing, removal) [40] to create a mask of
each CNB section. Once masked, each section was separated from the remainder of the
tissue on the WSI. The sections were then tiled (750 × 750 pixels), and each tile contained
a maximum of 10% background (Figure 1a(i)). Furthermore, the tiles were stain normal-
ized [41] (Figure 1a(ii)). A CNN was implemented to identify the tumor bed of each section
(Figure 1a(iii)). The CNN, outlined in a previous study [33], took H&E input images
of 750 × 750 pixels and returned a vector, which contained the probability of the tile be-
longing to the tumor bed. The probabilities were then used to re-build the original WSI,
outlining the location of the tumor bed (Figure 1a(iv)). Once the tumor bed was identified,
a tumor bed ratio (TBR) was calculated. The TBR of each CNB section was calculated by
dividing the tumor bed area (pixels) by the sum of all tumor bed areas (pixels) within
the WSI.
2.4. Instance Segmentation Network
Following tumor bed identification, the malignant nuclei within each tumor bed were
segmented (Figure 1a(v)). To segment the nuclei a mask regional convolutional neural
network (Mask R-CNN) was trained using the post-neo-adjuvant therapy breast cancer
(Post-NAT-BRCA) dataset [42]. The dataset contained 37 WSI with 120 ROIs from breast
resections of patients with residual invasive cancer following neoadjuvant therapy. Addi-
tionally, the dataset contained ground truth annotations performed by an expert pathologist
of lymphocytes, normal epithelial, and malignant epithelial cells within each ROI.
For this study, the annotated ROIs were re-sized to a uniform dimension of
512 × 512 pixels. The images were then randomly partitioned into a training set (90%) and
an independent test set (10%). The training images were further tiled to a dimension of
256 × 256 pixels. There were 480 training images in total, randomly split at a ratio of 80:20
between the training and validation datasets. Mask R-CNN was trained using residual
networks (ResNet-101) [43] as the CNN backbone, initialized with weights pre-trained
on the common objects in context (COCO) [44] dataset, and optimized with Stochastic
Gradient Descent (SGD) [45]. A random image augmentation pipeline was implemented
during training, which applied random combinations of flips, rotations, image scaling,
and blurring to the images. Furthermore, SGD was set to a learning rate of 1 × 10−4,
momentum of 0.9, and weight regularizer of 1 × 10−4. Mask R-CNN was trained until
convergence, and the performance was evaluated on the validation set during training.
Mask R-CNN was further evaluated using the unseen test dataset after training. Once
trained on the Post-NAT-BRCA dataset, Mask R-CNN provided instance segmentation of
the cells within the tumor bed for the 138 CNBs of the current study. Furthermore, only the
malignant nuclei identified within the tumor bed were retained for analysis for this study.
2.5. Spatial Feature Extraction
Following nuclei segmentation, object-wise features were computed using the nuclear
centroids; these included 52 spatial features per CNB section. There were three categories
of spatial features adapted by methods previously described by Doyle et al. (2008) [46]
and calculated using HistomicsTK [47]. Features were as follows: nuclear density features
(Figure 1b(vi)), nuclear graph features (Figure 1b(vii)), and nuclear count. There were
24 nuclear graph features, encompassing Voronoi diagram features, Delaunay triangulation
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features, and Minimum Spanning Tree (MST) features. Furthermore, 27 nuclear density
features were calculated, implementing k-dimensional (k–d) tree and ball tree algorithms.
Lastly, the number of nuclei per CNB section was counted.
2.6. Machine Learning
Separate ML models were trained using clinical and spatial features. The test dataset
was kept unseen during the development of each model, while the training dataset was
used for feature reduction and model training (Figure 1c). First, a check of multi-collinearity
was performed. A cross-correlation analysis was conducted, which identified highly corre-
lated continuous features (r2 ≥ 0.7). The highly correlated features were then correlated
with the outcome class (Nottingham grade) using point biserial; the feature with the highest
correlation coefficient was retained. The data were then partitioned at the patient level into
training (70%) and independent testing (30%) sets. The training data were standardized (Z-
score normalization), and the means and standard deviations were retained to standardize
the test set. To avoid class imbalance, the minority class (low-intermediate-grade BC [G1,
2]) was up-sampled using synthetic minority over-sampling technique (SMOTE) [48] and
borderline SMOTE [49] for clinical and spatial features, respectively.
The following ML models were trained and evaluated: K-nearest neighbor (K-NN),
logistic regression (LR), Naïve Bayes, support vector machines (SVM), random forest
classifier (RF), and extreme gradient boost (XGBoost). As Naïve Bayes was not suitable
for both continuous and ordinal features, it was excluded from clinical feature analysis.
Sequential forward feature selection (SFFS) was performed with each ML model to identify
the most discriminant features. The 10:1 rule for feature reduction was applied [50];
therefore, the maximum number of features permitted in the models was 10. SFFS was
performed for 100 iterations per model. During each iteration, a 10-fold cross-validation
(CV) technique was applied and evaluated using the area under the curve (AUC) of the
receiver operating characteristics (ROC) curve. The features that maximized the AUC
during each iteration were retained. The most discriminant features were identified as
the most frequently occurring feature set throughout the 100 iterations. Lastly, each ML
model’s hyperparameters were tuned using the randomized grid search (RGS) algorithm.
RGS was performed for 100 iterations; a 10-fold CV technique was applied and evaluated
using AUC during each iteration.
The final step was to develop an ensemble ML model, which would aggregate the
predicted probabilities of the clinical and spatial feature ML models. The challenge of
aggregating the predicted probabilities was addressed in two phases. First, as the spatial
models’ predictions were made at the level of the CNB section, each probability was
weighted based on the TBR and averaged per patient. Next, the weighting between
clinical and spatial model predictions was addressed. A range of values beginning at
zero and increasing linearly by 0.01 to one was implemented as weighted thresholds.
A zero threshold weighted the clinical model’s predicted probabilities at 100%, while
one weighted the spatial model’s predicted probabilities at 100%. A 10-fold CV strategy
was implemented using the training dataset at each threshold to determine the optimal
threshold. The threshold that maximized the AUC was then evaluated on the test set.
2.7. Software and Hardware
The software used for this study was written in Python programming language version
3.7.6 [51]. Using the Matterport package [52], Mask R-CNN was trained and implemented
with Keras version 2.3.1 [53] and Tensorflow version 2.1.0 [54]. Global cell graph features
were calculated using HistomicsTK version 1.0.5 [47], while nearest neighbor density
estimations were calculated using AstroML version 0.4.1 [55]. Furthermore, MLxtend
version 0.18.0 was used for SFFS [56]. Scikit learns version 0.24.1 [57] and XgBoost version
1.3.3 [58] were used for the remainder of the ML pipeline. All experiments were performed
on a workstation equipped with an AMD (Advanced Micro Devices, Inc., Santa Clara,
CA, USA) Ryzen Threadripper 1920X 12-Core Processor, 64GB of RAM, and a single
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The study cohort contained 138 patients who presented with invasive ductal carcinoma
(IDC), and a diagnostic core biopsy was collected from each subject for analysis. Of the
138 patients, four subjects (3%) had a G1 BC, 54 (39%) had G2, and 80 (58%) had G3 tumors.
As the primary aim of this study was to develop a computational pipeline to classify
high-risk BC cases (Nottingham G3), the low-intermediate grades (G1, 2) were grouped.
There were 58 (42%) patients classified as G1, 2, and 80 (58%) patients exhibited G3 tumors.
The distributions of the clinicopathological features are outlined in Table 1. In univari-
ate analysis, there were more ER-positive (p < 0.000) and PR-positive (p = 0.008) patients
with low and intermediate grade (G1, 2) tumors compared to high grade (G3) tumors.
Moreover, the distributions of the patients’ BC subtype, based on receptor status, with
respect to the entire cohort, ML training set, and independent hold-out (testing) set are
presented in Table S1. There were twenty patients (14%) whose subtype did not match
that of the four reported subtypes. The distributions of BC subtypes based on receptor
status ensured sufficient group representation within the training and testing sets since
histological grade varies according to these subtypes [59]. The clinicopathological features
included in ML modeling were age (years), ER (%), PR (%), and HER2 (+/−).
3.2. Mask R-CNN Segmentation
Figure 2 displays the performance of the Mask R-CNN on the testing set (Figure 2a,b)
and five representative H&E images from this study’s cohort (Figure 2c). Mask R-CNN
achieved a mean Aggregated Jaccard Index (AJI) of 0.53 and a mean average precision
(mAP) of 0.31. Furthermore, the network achieved F1, recall, and precision values of 0.65,
0.65, and 0.65, respectively, at an intersection over union (IoU) threshold of 0.5 and 0.40 at
an IoU threshold of 0.7. Figure 2a displays the H&E images, ground truth annotations, and
color-coded predictions for the lowest, median, and highest-scoring AJI images. The colors
are coded such that green represents true-positive pixels, red represents false-negatives
pixels, and blue represents false-positives pixels. In a qualitative review of the images, the
network tended to over-segment the median and lowest AJI images and often failed to
correctly segment nuclei where the image displayed staining irregularities. However, the
network performed well in segmenting well-defined nuclei.
3.3. Computationally Derived Spatial Features
Fifty-two computationally derived nuclear spatial features were extracted from each
CNB section. Representative features and group distributions are presented in Figure 2d.
The centroids of the segmented nuclei were used to extract three categories of spatial
features: nuclear density features, nuclear graph features, and nuclear count. In univariate
analysis, thirty spatial features were significantly different (p < 0.05) in CNB sections of
patients with G1, 2 compared to those with G3 (Figure 3). Of the thirty spatial features,
fifteen included nearest neighbor density features, six were Voroni diagram features, six
were Delaunay triangulation features, two were MST features, and significantly more
nuclei were identified in CNB sections of patients with G3 tumors.
3.4. Predictive Modeling Using Machine Learning
Independent ML models were trained using spatial and clinical features. The ML
models included Naïve Bayes, K-NN, LR, RF, SVM, and XGBoost; however, as Naïve Bayes
is not suited for both continuous and ordinal features, it was excluded from clinical mod-
eling. One hundred iterations of SFFS were performed to identify the most discriminant
features and reduce the random effect of feature selection. A 10-fold CV strategy was
implemented during each iteration, and the final feature sets were identified as the most
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frequently occurring features during the 100 iterations. Table 2 displays the most frequently
occurring feature sets.
Table 1. Clinicopathological characteristics of the patients with G1, 2 and G3 breast cancer tumors.
Bolded values represent statistical significance (p < 0.05). Abbreviations: G1, 2, Nottingham grade
1 and 2; G3, Nottingham grade 3; SD, standard deviation; y, years; ER, estrogen receptor; PR,
progesterone receptor; HER2, human epidermal growth factor.
Patient Clinicopathological
Characteristics
Study Cohort (n = 138)
G1, 2 (n = 58) n (%) G3 (n = 80) n (%) p-Value
Age
Mean Age ± SD (y) 51.6 ± 10.8 50.3 ± 9.2 0.423
≤50 years 23 (39.7) 39 (48.8)
0.289>50 years 35 (60.3) 41 (51.3)
Menopausal Status
Pre 30 (51.7) 38 (47.5)
0.624Post 28 (48.3) 42 (52.5)
Tumor Laterality
Left 25 (43.1) 38 (47.5)
0.609Right 33 (56.9) 42 (52.5)
Receptor Status
Median ER ± SD (%) 90 ± 44.1 0 ± 43.9 <0.000
ER-positive 43 (74.1) 34 (42.5)
<0.000ER-negative 15 (25.9) 46 (57.5)
Median PR ± SD (%) 4 ± 42.8 0 ± 36.3 0.013
PR-positive 35 (60.3) 30 (37.5)
0.008PR-negative 23 (39.7) 50 (62.5)
HER2-positive 26 (44.8) 39 (48.8)
0.649HER2-negative 32 (55.2) 41 (51.3)
Tumor Size
0.445Mean Size ± SD (mm) 48.3 ± 27.8 44.5 ± 25.1
Clinical T Stage
1 5 (8.6) 4 (5.0)
0.314
2 32 (55.2) 54 (67.5)
3 21 (36.2) 22 (27.5)
4 0 (0.0) 0 (0.0)
Clinical N Stage
0 12 (20.7) 28 (35.0)
0.183
1 40 (69.0) 46 (57.5)
2 6 (10.3) 6 (7.5)
3 0 (0.0) 0 (0.0)
Node Status
Node-positive 46 (79.3) 52 (65.0)
0.067Node-negative 12 (20.7) 28 (35.0)
Inflammatory Breast Cancer
Yes 5 (8.6) 8 (10.0)
0.784No 53 (91.4) 72 (90.0)
Bolded values represent statistical significance (p < 0.05).
The RGS algorithm was used to tune each model’s hyperparameters. The hyperpa-
rameters that maximized AUC during 100 iterations of parameter selection are displayed
in Table S2. The performance metrics, which represent the patient level Nottingham
grade, of the clinical, spatial, and ensemble ML models are displayed in Table 3 and Table
S3. Representative AUCs and weighting parameters are shown in Figure 4. The perfor-
mance of the clinical ML models ranged from an AUC of 0.5–0.77 and 0.64–0.78 for the
spatial models evaluated on the test set. The LR and XGBoost clinical models scored high-
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est (AUC = 0.77, accuracy = 74%) on all metrics except for sensitivity and false-negative
ratio, in which RF performed better. The best performing spatial model was XGBoost
(AUC = 0.78, accuracy = 71%). All combinations of clinical and spatial ML models were
evaluated in the development of the ensemble model. The ensemble model that performed
best on the test set combined the LR clinical model and RF spatial model at a threshold of
0.37. The threshold weighting indicated that the clinical model predictions were weighted
at 63%, while the spatial model predictions were weighted at 37%. The LR clinical model
included ER (%) and PR (%) in the final analysis. The RF spatial model included the follow-
ing features in the final analysis: nuclear count, Voronoi max distance standard deviation
(SD), Voronoi max distance disorder, Density neighbors in distance one disorder, Density
neighbors in distance 4 SD, Density distance for neighbors two minimum-maximum ratio,
Density distance for neighbors two disorder, Density minimum, and Density median. The
ensemble model achieved a mean AUC of 0.96 ± 0.12 and accuracy of 88 ± 14% during the
10-fold CV on the training data at a threshold of 0.37. The model further achieved an AUC
of 0.84, accuracy of 78.57%, sensitivity of 83%, and specificity of 72% on the test set.
Figure 2. Instance segmentation of malignant nuclei by Mask regional convolutional neural network (Mask R-CNN) and
representative feature extraction. (a,b) Mask R-CNN performance, evaluated on the hold-out (test) set. The highest, median,
and lowest scoring AJI images from the Post-NAT-BRCA dataset are displayed. The predicted cells are color-coded such
that green denotes true-positive, blue false-positive, and red false-negative pixels. Average precision over ten intersections
over union thresholds is also displayed. (c) Representative H&E images from five patients and their respective malignant
nuclei masks are displayed. (d) The Delaunay triangulation features, Voronoi diagram features, and density features
were calculated using the centroids of the segmented malignant nuclei. Abbreviations: H&E, hematoxylin and eosin; AJI,
Aggregated Jaccard Index.
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Figure 3. Combined box and whisker and swarm plots of the statistically significant (p < 0.05) spatial features. Abbreviations:
stddev, standard deviation; Min, minimum; Max, maximum; MST, Minimum Spanning Tree; a.u., Arbitrary units; G1, 2,
Nottingham grade 1 and 2; G3, Nottingham grade 3.
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Table 2. Most frequently occurring spatial and clinical feature sets. One hundred iterations of sequential forward feature selection were performed per model. The most frequently
occurring clinical and spatial feature sets are reported. Abbreviations: K-NN, K-nearest neighbor; LR, logistic regression; RF, random forest classifier; SVM, support vector machine;
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Table 3. Performance measures of machine learning models, trained using clinical and spatial features sets. All models were trained using 10-fold cross-validation and tested on an
independent hold-out set. The three highest performing ensemble models are reported. All performance measures are reported at the patient level. Abbreviations: K-NN, K-nearest
neighbor; LR, logistic regression; RF, random forest classifier; SVM, support vector machine; XGBoost, extreme gradient boost; AUC, area under the curve; SD, standard deviation; ACC,
accuracy; Sn, sensitivity; Sp, specificity; Prev, prevalence; FNR, false-negative rate; FPV, false-positive rate; PPV, positive predictive value; NPV, negative predictive value; FDR, false
discovery rate; FOR, false omission rate; LR+, positive likelihood ratio; LR-, negative likelihood ratio; DOR, diagnostic odds ratio.
Feature
Set Model




















(%) LR+ LR- DOR f1
Clinical
K-NN 0.66 ± 0.16 62 ± 14 0.62 64.29 75.00 50.00 57.14 25.00 50.00 66.67 60.00 33.33 40.00 1.50 0.50 3.00 0.71
LR 0.66 ± 0.22 64 ± 19 0.77 73.81 75.00 72.22 57.14 25.00 27.78 78.26 68.42 21.74 31.58 2.70 0.35 7.80 0.77
RF 0.68 ± 0.15 59 ± 14 0.56 66.67 83.33 44.44 57.14 16.67 55.56 66.67 66.67 33.33 33.33 1.50 0.38 4.00 0.74
SVM 0.64 ± 0.25 52 ± 16 0.50 66.67 75.00 55.56 57.14 25.00 44.44 69.23 62.50 30.77 37.50 1.69 0.45 3.75 0.72
XGBoost 0.63 ± 0.23 59 ± 16 0.77 73.81 75.00 72.22 57.14 25.00 27.78 78.26 68.42 21.74 31.58 2.70 0.35 7.80 0.77
Spatial
Naïve Bayes 0.65 ± 0.07 59 ± 6 0.68 64.29 87.50 33.33 57.14 12.50 66.67 63.64 66.67 36.36 33.33 1.31 0.38 3.50 0.74
K-NN 0.87 ± 0.03 76 ± 3 0.64 66.67 66.67 66.67 57.14 33.33 33.33 72.73 60.00 27.27 40.00 2.00 0.50 4.00 0.70
LR 0.67 ± 0.04 62 ± 5 0.73 66.67 62.50 72.22 57.14 37.50 27.78 75.00 59.09 25.00 40.91 2.25 0.52 4.33 0.68
RF 0.88 ± 0.04 79 ± 5 0.75 64.29 79.17 44.44 57.14 20.83 55.56 65.52 61.54 34.48 38.46 1.43 0.47 3.04 0.72
SVM 0.79 ± 0.06 77 ± 5 0.69 69.05 75.00 61.11 57.14 25.00 38.89 72.00 64.71 28.00 35.29 1.93 0.41 4.71 0.73
XGBoost 0.88 ± 0.03 79 ± 3 0.78 71.43 87.50 50.00 57.14 12.50 50.00 70.00 75.00 30.00 25.00 1.75 0.25 7.00 0.78
Ensemble
LR + RF 0.96 ± 0.12 88 ± 14 0.84 78.57 83.33 72.22 57.14 16.67 27.78 80.00 76.47 20.00 23.53 3.00 0.23 13.00 0.82
LR + XGBoost 0.70 ± 0.23 56 ± 14 0.84 73.81 75.00 72.22 57.14 25.00 27.78 78.26 68.42 21.74 31.58 2.70 0.35 7.80 0.77
XGBoost + RF 0.96 ± 0.13 92 ± 13 0.83 73.81 87.50 55.56 57.14 12.50 44.44 72.41 76.92 27.59 23.08 1.97 0.23 8.75 0.79
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Figure 4. Receiver operating characteristics (ROC) curve and area under the curve (AUC) of the
top performing machine learning models trained with clinical and spatial feature sets. (a left) ROC
and AUC of XGBoost, the top performing classifier using clinical features. (a right) ROC and AUC
of XGBoost, the top performing classifier using spatial features. (b–d) The top three performing
ensemble models. (b) AUC vs. Threshold of LR+RF, with an optimal threshold of 37% (left). ROC
and AUC of LR+RF (right). (c) AUC vs. Threshold of LR+XGBoost, with an optimal threshold of
10% (left). ROC and AUC of LR+XGBoost (right). (d) AUC vs. Threshold of XGBoost+RF, with an
optimal threshold of 46% (left). ROC and AUC of XGBoost+RF (right). Abbreviations: ROC, Receiver
Operating Characteristic curve; AUC, Area Under the Curve; LR, Logistic regression; RF, random
forest classifier; XGBoost, Extreme Gradient Boost.
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4. Discussion
In this study, we demonstrated that object-level (spatial) features derived from breast
tumor WSI were associated with histologic grade. The results of our experiments showed
good classification accuracy using machine learning to identify high Nottingham grade
(G3) versus low- and intermediate-grade (G1,2) tumors. This study also demonstrated
increased classification performances when ER/PR/HER2 pathologic biomarkers were
included in the model.
In related works, previous approaches have been proposed for automatic histologic
grading, including the use of various segmentation techniques, feature sets, group label-
ing conventions, and classification models [36,46,60–64]. Wan et al., examined 106 breast
tumors and employed a hybrid active contour method to carry out segmentation tasks,
using global and local image information [60]. Multi-level features were extracted, includ-
ing texture (pixel-level), spatial (object-level), and semantic-level features derived from
CNNs [60]. A SVM model was used for binary classifications (e.g., G1 versus G2,3), and
another set of experiments were built on this pipeline to construct a cascade ensemble
framework to classify G1 vs. G2 vs. G3. The results of their study showed an AUC of
0.87 ± 0.11 for binary classification of G3 from G1,2 tumors, and multivariate classifi-
cation demonstrated an accuracy of 0.69 ± 0.12 for each Nottingham grade [60]. Other
studies by Doyle et al., yielded an SVM classifier accuracy of 0.70 to distinguish low-
versus high-grade tumors [46], and Cao et al., reported an accuracy of 0.90 by testing a
combination of pixel-, object-, and semantic-level feature sets [61]. Recent research from
Couture et al., implemented a DL-based segmentation step into their analysis pipeline for
a large patient cohort (n = 579) [36]. Among histologic grade, other labels included ER
status, histologic type, and molecular markers from their study population. Imaging data
were yielded from digitized tissue microarray cores (TMA). The CNN backbone consisted
of a VGG16 architecture for segmentation and feature extraction, followed by an ensemble
SVM classifier. Nottingham labels were clustered into binary classes, which grouped
patients as G1,2 versus G3. Ground truth labels were subjected to kappa statistics for
interobserver agreement testing. With respect to histologic grade labels, applying a fixed
threshold (0.8) showed an accuracy of 82% for detecting high-grade tumors [36]. Similarly,
Yan et al., implemented an end-to-end computational pipeline, first using a deep learning
framework for nuclear segmentation, then a Nuclei-Aware Network (NaNet) consisting of
a VGG16 (Visual Geometry Group 16) backbone for feature representation learning [63].
Their results showed high classification accuracy (92.2%) from the model to distinguish
each Nottingham category [63].
In comparison to these previous studies, our study aimed to focus on ML classification
tasks based on object-wise spatial features and standard pathologic biomarkers; this was
carried out by building an end-to-end ML pipeline consisting of a CNN-based segmen-
tation framework, then computing imaging features from computed regions of interest.
Finally, we exploited ML classification modeling to find features associated with the group
labels. We compared and tested multiple classification models using these feature sets and
found that the XGBoost model performed the best to automatically classify high-grade
tumors; however, the ensemble models also performed well in correctly grading tumors.
In designing this study, it was imperative to ensure sufficient representations within the
high-grade class to train our model. Additionally, the group classes were determined based
on its clinical relevance. Specifically, high-grade-tumors impact treatment and prognostic
endpoints. Cortazar et al. demonstrated higher rates of pathologic complete response
in high-grade tumors compared to those with grade 1/2 tumors for women treated with
NAC [4]. Their pooled analysis also showed that exhibiting high-grade residual disease
following NAC portended poorer survival outcomes [4]. This study also showed better
classification performances by including standard biomarkers (ER/PR/HER2) in ML mod-
els. This may be explained by the association between high-grade tumors and aggressive
subtypes, such as triple negative [65,66] and HER2-amplified [67] breast cancer.
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Establishing robust and high-performance CAD systems in pathology has the potential
to transform personalized medicine [68]. Indeed, pathologic evaluation is the gold-standard
to derive a diagnosis and provides important information to steer treatment decisions
in breast oncology, both in the neoadjuvant and adjuvant setting. Key opportunities for
CADs in pathology include remote analysis and telepathology, which can bring expert
review and automation to rural or underserviced regions. Additionally, computational
pathology has the promise of advancing medical education curricula (e.g., provide learning
materials and case series) and can facilitate quality initiatives in the laboratory and clinic as
a second verification system to manual annotations [68,69]. Furthermore, CADs have the
opportunity to assist with the reproducibility concerns of the current Nottingham grading
guidelines [2]. Currently, manual microscopic review yields extensive variations in inter-
observer variability, with kappa values reported from fair to strong (0.43 to 0.85) [2,9,10].
Moreover, there is higher discordance in differentiating between G2 and G3 tumors and
only fair interobserver agreement for classifying G2 tumors (K = 0.375) [9]. In the era of per-
sonalized oncology, digital biomarkers from pathology CADs may complement prediction
and prognostic models and can be indexed into federated libraries to carry out population-
based studies. Utilization of computational tools can also expedite the workflow, increase
efficiency in the laboratory, and prioritize cases for review. Furthermore, it would provide
a robust method of grading tumors, which would standardize the pathological workflow.
Despite the array of opportunities, the challenges of digital pathology analysis include
mechanical limitations of the imaging systems. There is a risk of suboptimal image quality
(e.g., blurry images and software-generated artifacts) that have downstream effects on ex-
tracting features. Other considerations include determining optimal magnification and the
use of multiplanar (cross sectional) views. Lastly, standardizing pre-processing methods is
imperative to regulate staining intensities on variable samples as well as to mitigate the
challenges of segmenting abutting or overlapping nuclei [70].
Limitations of this present study include a smaller patient cohort and the fact that
models were trained and tested at a single institution. Future work will involve collection
of data from annotated external data sets. As breast cancer represents an array of biological
subtypes, another limitation includes the inability to generalize these findings with respect
to BC intrinsic subtypes, e.g., luminal A, luminal B, triple negative, and HER2-amplified
tumors. A larger cohort with sufficient samples will permit subtype analysis and aid
feature learning and modeling. Another limitation of our study involves challenges with
scoring intermediate-grade tumors, which have shown greater reporting variability among
pathologists [9]. Thus, the grouping mechanism used in this present study (i.e., G1,2) could
affect the classification performances of our model. Notwithstanding these limitations,
this study demonstrates similar classification accuracy in comparison to previous studies
and builds the framework for future work to include other biomarkers into the automatic
annotation pipeline.
Prospective work may include refining computational frameworks across the pipeline
to achieve optimal classification performances. Current efforts include automated assess-
ment of tubule formation, nuclear pleomorphism, and mitotic activity. Adding spatial
and pathologic feature sets to those experiments could potentially enhance the accuracy of
grading tumors; this is achieved by adding meaningful features to the modeling dataset.
Other areas of importance include training algorithms for ILC, as these tumors exhibit
different morphological characteristics and spatial organization.
5. Conclusions
Developing CADs in pathology within the framework of AI and quantitative digital
pathology imaging markers is poised to transform laboratory and clinical practices in
oncology. Opportunities include case stratification, expedited review and annotation, and
outputting meaningful models to guide treatment decisions and prognosticate patterns of
breast cancer relapse and survival. To achieve this, robust and standardized computational,
clinical, and laboratory practices need to be established in tandem and tested across
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multiple partnering sites for final validation. Nevertheless, with increased capacity in
data informatics and processing, computational pathology will have an impact on breast
cancer management.
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